© 2010 Peggy Greb/Science Photo Library2010Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company\'s public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Since the first issue of this journal in August 2001, we have published at least 60 Review and Personal View papers per year, innumerable commentaries, letters, and Clinical Pictures, more news than is fit to print, but (depending on your view of the status of meta-analyses) not a single original research paper. All that will change on the ninth anniversary of the journal\'s launch when we begin publication of primary research articles.

The infectious diseases landscape has changed substantially in the past 9 years. Shortly after this journal launched, the events of September 11, 2001, and subsequent sending of anthrax spores through the US mail, led to renewed concern about bioterrorism. The money invested in stockpiling drugs, and developing new diagnostics and new vaccines against smallpox was arguably misdirected, but probably had a beneficial fallout. 2003 saw an epidemic of severe acute respiratory syndrome that led to international alarm and adversely affected the global economy. Fortunately, following unprecedented multilateral collaboration, the causative coronavirus was identified rapidly and the outbreak halted. The same year also saw the reappearance of the highly pathogenic avian influenza virus H5N1. The virus continues to take a small but steady toll of human life, leading to fears that it might cause the next influenza pandemic. The work that went into preparedness against this event proved worthwhile when a pandemic did happen in 2009, caused---unpredictably---by a strain of influenza H1N1. Antibiotic resistance remains a potent threat to human health. Although we have not yet seen the return to the pre-antibiotic era predicted at the start of the millennium, community-acquired meticillin-resistant *Staphylococcus aureus* has become commonplace in some settings, and the spread of antibiotic-resistant Gram-negative infections seems inexorable.

Among the world\'s poorest people, AIDS, tuberculosis, and malaria continue to cause an unacceptable death toll. Yet even here there has been progress. Thanks to increased funding (as yet still inadequate) from the world\'s richer countries, the number of people receiving antiretroviral drugs has risen by millions in the past few years. Tuberculosis control has been complicated by the emergence of multidrug-resistant and extensively drug resistant strains of *Mycobacterium tuberculosis*, but after faltering progress new drugs and vaccines are on the horizon. And in places the burden of malaria seems to be falling, thanks perhaps to the availability of artemisinin combination therapies and distribution of bednets.

As noted elsewhere in this issue, money dedicated to combating the so-called neglected tropical diseases is far from sufficient but substantially more than it once was. Another partial success story---with much work still left to do---has been the greatly increased use of [vaccines against childhood diseases in developing countries](10.1016/S1473-3099(10)70033-5), as we described last month.

Explosive growth of activity in genomics and bioinformatics has led to the realisation that human beings interact in previously unimagined ways with a vast community of microorganisms living in, on, and around us. Fresh insight into the role of the microbiome in disease processes will certainly emerge from this work.

It is against this background of ever-expanding research activity that the journal will begin publishing original research articles. From June 1, 2010, *The Lancet Infectious Diseases* will consider primary research submissions that are likely to influence clinical practice; we will not consider any such articles submitted before this date. The journal will give highest priority to randomised clinical trials, followed by---but not limited to---meta-analyses, case-control and cohort studies, and epidemiological investigations. In vitro and animal studies are unlikely to be considered. All submissions judged eligible by the journal\'s editorial team will be fast-track peer reviewed within 72 h. If accepted, a research article will be published within 4--8 weeks. We will aim to publish all accepted articles online before they appear in print. We plan to publish the first research article online in July and in print in the August issue.

The journal will continue its comprehensive coverage of infectious diseases by publishing Review and Personal View papers, editorials, commentaries, letters, news, and media reviews. Revised information for authors will be published next month on the journal\'s website.

By adding fast-track peer review for original research, we intend to build on the position of *The Lancet Infectious Diseases* as the most highly rated in the field in terms of impact factor, and provide a competitive service for authors who wish to rapidly communicate their research findings to the worldwide infectious diseases community.
